Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

10/2/2019 6:58:50 AM Merck: FDA To Review Two Applications For DIFICID - Quick Facts

10/2/2019 6:34:54 AM Merck Says FDA Accepts Two Applications For DIFICID

9/30/2019 10:54:43 AM AstraZeneca : Lynparza Reduces Risk Of Disease Progression In HRR Gene Mutations

9/30/2019 2:25:08 AM AstraZeneca, MSD Report Positive Results From Phase III Trial With Lynparza

9/30/2019 2:04:55 AM AstraZeneca And Merck Announce Positive Results From Phase III PAOLA-1 Trial

9/23/2019 3:17:03 AM Merck: CHMP Positive Opinion For Rebif Label Amendment During Pregnancy As Clinically Needed And While Breastfeeding

9/20/2019 7:10:26 AM FDA Approves Merck's SNDAs For PIFELTRO And DELSTRIGO - Quick Facts

9/20/2019 6:47:51 AM Merck: FDA Approves SNDAs For PIFELTRO And DELSTRIGO

9/18/2019 9:05:53 AM FDA, Canada, Australia Collaborate On Cancer Drugs Review

9/18/2019 3:51:24 AM FDA Makes 1st Approval Under Project Orbis, KDMN On Watch, TBIO Down After-hrs

9/17/2019 7:18:19 AM Merck: FDA Grants Priority Review For Investigational Ebola Vaccine

9/17/2019 6:58:58 AM Merck Says FDA Accept BLA And Granted Priority Review For Ebola Vaccine V920

9/9/2019 9:30:03 AM Merck & Co To Present At The Morgan Stanley Conference; Webcast At 10:30 AM ET

9/4/2019 7:22:47 AM Merck: European Commission Approves KEYTRUDA, Inlyta Combination To Treat RCC

9/4/2019 7:02:22 AM Merck Says European Commission Approves KEYTRUDA In Combination With Inlyta

8/22/2019 6:51:54 AM Merck Highlights New Data From Leading Lung Cancer Clinical Development Program At IASLC 2019

8/14/2019 2:35:04 AM AstraZeneca Reports Breakthrough Therapy Designation For Calquence - Quick Facts

8/7/2019 3:50:01 AM AstraZeneca, Merck Report Positive Phase III Trial Results Of Lynparza

8/7/2019 2:08:35 AM AstraZeneca, Merck Announce Positive Results From Phase III PROfound Trial Of Lynparza

7/31/2019 8:12:47 AM Merck Says FDA Okays New Monotherapy Indication For KEYTRUDA